513 related articles for article (PubMed ID: 20139821)
21. Comparative study of FDG PET/CT and conventional imaging in the staging of rhabdomyosarcoma.
Tateishi U; Hosono A; Makimoto A; Nakamoto Y; Kaneta T; Fukuda H; Murakami K; Terauchi T; Suga T; Inoue T; Kim EE
Ann Nucl Med; 2009 Feb; 23(2):155-61. PubMed ID: 19225939
[TBL] [Abstract][Full Text] [Related]
22. Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT.
Metser U; Even-Sapir E
Semin Nucl Med; 2007 May; 37(3):206-22. PubMed ID: 17418153
[TBL] [Abstract][Full Text] [Related]
23. 18F-FDG PET and CT/MRI in oral cavity squamous cell carcinoma: a prospective study of 124 patients with histologic correlation.
Ng SH; Yen TC; Liao CT; Chang JT; Chan SC; Ko SF; Wang HM; Wong HF
J Nucl Med; 2005 Jul; 46(7):1136-43. PubMed ID: 16000282
[TBL] [Abstract][Full Text] [Related]
24. Correlation of 18F-FLT uptake with tumor grade and Ki-67 immunohistochemistry in patients with newly diagnosed and recurrent gliomas.
Yamamoto Y; Ono Y; Aga F; Kawai N; Kudomi N; Nishiyama Y
J Nucl Med; 2012 Dec; 53(12):1911-5. PubMed ID: 23081994
[TBL] [Abstract][Full Text] [Related]
25. Role of whole body positron emission tomography/computed tomography scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site.
Pelosi E; Pennone M; Deandreis D; Douroukas A; Mancini M; Bisi G
Q J Nucl Med Mol Imaging; 2006 Mar; 50(1):15-22. PubMed ID: 16557200
[TBL] [Abstract][Full Text] [Related]
26. Glioma recurrence versus radiation necrosis? A pilot comparison of arterial spin-labeled, dynamic susceptibility contrast enhanced MRI, and FDG-PET imaging.
Ozsunar Y; Mullins ME; Kwong K; Hochberg FH; Ament C; Schaefer PW; Gonzalez RG; Lev MH
Acad Radiol; 2010 Mar; 17(3):282-90. PubMed ID: 20060750
[TBL] [Abstract][Full Text] [Related]
27. ¹¹C-methionine and ¹⁸F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of patients with suspected primary and residual/recurrent gliomas.
Li DL; Xu YK; Wang QS; Wu HB; Li HS
Chin Med J (Engl); 2012 Jan; 125(1):91-6. PubMed ID: 22340472
[TBL] [Abstract][Full Text] [Related]
28. Estimation of patient dose in (18)F-FDG and (18)F-FDOPA PET/CT examinations.
Kaushik A; Jaimini A; Tripathi M; D'Souza M; Sharma R; Mishra AK; Mondal A; Dwarakanath BS
J Cancer Res Ther; 2013; 9(3):477-83. PubMed ID: 24125986
[TBL] [Abstract][Full Text] [Related]
29. 18F-FDOPA PET/CT for detection of recurrence in patients with glioma: prospective comparison with 18F-FDG PET/CT.
Karunanithi S; Sharma P; Kumar A; Khangembam BC; Bandopadhyaya GP; Kumar R; Gupta DK; Malhotra A; Bal C
Eur J Nucl Med Mol Imaging; 2013 Jul; 40(7):1025-35. PubMed ID: 23525498
[TBL] [Abstract][Full Text] [Related]
30. (18)F-FDOPA PET for differentiating recurrent or progressive brain metastatic tumors from late or delayed radiation injury after radiation treatment.
Lizarraga KJ; Allen-Auerbach M; Czernin J; DeSalles AA; Yong WH; Phelps ME; Chen W
J Nucl Med; 2014 Jan; 55(1):30-6. PubMed ID: 24167081
[TBL] [Abstract][Full Text] [Related]
31. Relationship among glycolytic phenotype, grade, and histological subtype in ovarian carcinoma.
Karantanis D; Allen-Auerbach M; Czernin J
Clin Nucl Med; 2012 Jan; 37(1):49-53. PubMed ID: 22157028
[TBL] [Abstract][Full Text] [Related]
32. Standardized uptake value based evaluation of lymphoma by FDG and FLT PET/CT.
Wang R; Zhu H; Chen Y; Li C; Li F; Shen Z; Tian J; Yu L; Xu B
Hematol Oncol; 2014 Sep; 32(3):126-32. PubMed ID: 23996464
[TBL] [Abstract][Full Text] [Related]
33. Comparison of the effect of positive and negative oral contrast agents on (18)F-FDG PET/CT scan.
Sun XG; Huang G; Liu JJ; Wan LR
Hell J Nucl Med; 2009; 12(2):115-8. PubMed ID: 19675862
[TBL] [Abstract][Full Text] [Related]
34. [18F]3'-deoxy-3'-fluorothymidine PET for the diagnosis and grading of brain tumors.
Choi SJ; Kim JS; Kim JH; Oh SJ; Lee JG; Kim CJ; Ra YS; Yeo JS; Ryu JS; Moon DH
Eur J Nucl Med Mol Imaging; 2005 Jun; 32(6):653-9. PubMed ID: 15711980
[TBL] [Abstract][Full Text] [Related]
35. Comparative diagnostic accuracy of contrast-enhanced MRI and (18)F-FDOPA PET-CT in recurrent glioma.
Karunanithi S; Sharma P; Kumar A; Khangembam BC; Bandopadhyaya GP; Kumar R; Goenka A; Gupta DK; Malhotra A; Bal C
Eur Radiol; 2013 Sep; 23(9):2628-35. PubMed ID: 23624623
[TBL] [Abstract][Full Text] [Related]
36. 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors.
Jacobs AH; Thomas A; Kracht LW; Li H; Dittmar C; Garlip G; Galldiks N; Klein JC; Sobesky J; Hilker R; Vollmar S; Herholz K; Wienhard K; Heiss WD
J Nucl Med; 2005 Dec; 46(12):1948-58. PubMed ID: 16330557
[TBL] [Abstract][Full Text] [Related]
37. Solitary hepatic metastasis from medullary thyroid carcinoma mimicking atypical hemangioma: insights from multimodality diagnostic approach by MRI, F-18 FDG and F-18 FDOPA PET/CT.
Imperiale A; Greget M; Chabrier G; Keomany J; Rust E; Detour J; Pessaux P; Goichot B
Clin Nucl Med; 2010 Jun; 35(6):434-7. PubMed ID: 20479594
[No Abstract] [Full Text] [Related]
38. 11C-methionine (MET) and 18F-fluorothymidine (FLT) PET in patients with newly diagnosed glioma.
Hatakeyama T; Kawai N; Nishiyama Y; Yamamoto Y; Sasakawa Y; Ichikawa T; Tamiya T
Eur J Nucl Med Mol Imaging; 2008 Nov; 35(11):2009-17. PubMed ID: 18542957
[TBL] [Abstract][Full Text] [Related]
39. ¹⁸F-FLT and ¹⁸F-FDOPA PET kinetics in recurrent brain tumors.
Wardak M; Schiepers C; Cloughesy TF; Dahlbom M; Phelps ME; Huang SC
Eur J Nucl Med Mol Imaging; 2014 Jun; 41(6):1199-209. PubMed ID: 24604590
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic usefulness of 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography in recurrent brain tumor.
Hong IK; Kim JH; Ra YS; Kwon DH; Oh SJ; Kim JS
J Comput Assist Tomogr; 2011; 35(6):679-84. PubMed ID: 22082535
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
